

Request for Proposals (RFP): Janssen Biotech, Inc.

Funding is available to support innovative and interactive nationwide certified medical education (CME) educational series that is designed to inform community healthcare providers about appropriate diagnosis and frontline treatment of newly diagnosed patients with multiple myeloma.

Grant Application Deadline: June 28, 2021

Therapeutic Area:	Multiple Myeloma
Treatment Focus:	Overall learning objectives will focus on education on diagnosis and treatment options of patients with multiple myeloma. This will include: <ul style="list-style-type: none">• Discussing treatment guidelines• Discussing the frontline treatment of newly diagnosed multiple myeloma patients• Treatment administration (e.g., subcutaneous)
Delivery Format:	Educational series (nationwide) – Interactive: case-based, workshops, small group discussion, ask the expert, etc.
Target Audience:	Community Healthcare Providers, Allied Health Professionals, or Advanced Practice Providers
Timelines:	Program Start Date: Q3 2021
Funding Requirements:	Multi-support programs
Eligibility Criteria:	<u>CME/CE applicants must fall into one of the following categories with a bona fide interest in hematology/oncology or other specialties:</u> Academic institutions (medicine, pharmacy or nursing) Teaching hospitals Medical societies Professional associations Government agencies Medical education companies (accredited)
Submission Link:	Submissions to Janssen Oncology can be completed online at: https://www.janssen.com/us/grants-and-giving/educational-grants/oncology
Special Note:	Due to the ongoing COVID-19 pandemic, it is encouraged that proposals include contingency plans for virtual delivery. Program may include both live and virtual programs.

For any questions related to this RFP, please email OncologyGrants@its.jnj.com.
